FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System

MT Newswires Live09-14

Halozyme Therapeutics (HALO) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration.

The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the blood when administered subcutaneously, and a safety and efficacy profiles on par with the intravenous formulation for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

The company's shares were up over 2% in recent trading.

Price: 61.95, Change: +1.41, Percent Change: +2.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467408892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-14 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467408892","market":"sg","top_or_hot":-1,"title":"FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System","media":"MT Newswires Live","content":"<html><body><p> Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HALO) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration.</p><p>The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the blood when administered subcutaneously, and a safety and efficacy profiles on par with the intravenous formulation for both relapsing multiple sclerosis and primary progressive multiple sclerosis.</p><p>The company's shares were up over 2% in recent trading.</p><p>Price: 61.95, Change: +1.41, Percent Change: +2.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-14 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Halozyme Therapeutics (HALO) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467408892","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467408892","pubTimestamp":1726255528,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Halozyme Therapeutics  said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration.The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the blood when administered subcutaneously, and a safety and efficacy profiles on par with the intravenous formulation for both relapsing multiple sclerosis and primary progressive multiple sclerosis.The company's shares were up over 2% in recent trading.Price: 61.95, Change: +1.41, Percent Change: +2.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"FDA批准罗氏使用Halozyme递送系统治疗多发性硬化症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"Halozyme Therapeutics (HALO) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration.The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the blood when administered subcutaneously, and a safety and efficacy profiles on par with the intravenous formulation for both relapsing multiple sclerosis and primary progressive multiple sclerosis.The company's shares were up over 2% in recent trading.Price: 61.95, Change: +1.41, Percent Change: +2.33","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467408892"}